Treatment of Fungal Infections

  • G. P. Bodey
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

The frequency of fungal infections in patients with acute leukemia has increased substantially during the past decade. For many years, these infections occurred predominantly among patients with advanced leukemia who were no longer responding to antileukemic chemotherapy. Recently systemic infections are occurring during the initial remission induction period. In one study, the major cause offailure of initial antileukemic therapy was death due to infection and 40% of these deaths were due to fungal infection [1]. The syndrome of chronic disseminated candidiasis (hepatosplenic candidiasis), a rare infection in the 1960s, has increased substantially during the last decade. Furthermore, many new pathogens have been recognized in these patients [2].

Keywords

Fungal Infection Antifungal Agent Acute Leukemia Neutropenic Patient Liposomal Amphotericin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Estey EH, Keating MJ, McCredie KB, Bodey, GP, Freireich, EJ (1982) Causes of initial remission induction failure in acute myelogenous leukemia. Blood 60: 309–315PubMedGoogle Scholar
  2. 2.
    Anaissie, EJ, Bodey, GP, Rinaldi, MG (1989) Emerging fungal pathogens. Eur J Clin Microbiol Inf Dis 8: 323–330CrossRefGoogle Scholar
  3. 3.
    Bodey GP (1984) Candidiasis in cancer patients. In: Bodey GP: Candidiasis: A Growing Concern. Am J Med 77: 13–19Google Scholar
  4. 4.
    Maksymiuk A W, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP (1984) Systemic candidiasis in cancer patients. In: Bodey GP: Candidiasis: A Growing Concern. Am J Med 77: 20–27Google Scholar
  5. 5.
    Bodey GP, Rodriguez V, Chang HY, Narboni G (1978) Fever and infection in leukemic patients. A study of 494 consecutive patients. Cancer 41: 1610–1622PubMedCrossRefGoogle Scholar
  6. 6.
    Bodey GP (1988) The emergence of fungi as major hospital pathogens (Lowbury Lecture: 1st International Conference on the Hospital Infection Society. London, Sept 1987). J Hosp Infect 11: 411–426PubMedCrossRefGoogle Scholar
  7. 7.
    Dick JD, Merz WG, Saral R (1980) Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 18: 158–163PubMedGoogle Scholar
  8. 8.
    Powderly WG, Kobayashi GS, Herzig GP, Medoff G (1988) Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 84: 826–832PubMedCrossRefGoogle Scholar
  9. 9.
    Pappagianis D, Collins MS, Hector R, Remington J (1979) Development of resistance to amphotericin B in Candida /usitaniae infecting a human. Antimicrob Agents Chemother 16: 123–126PubMedGoogle Scholar
  10. 10.
    Denning DW, Tucker RM, Hanson LA (1989) Treatment of Invasive Aspergillosis with I traconazole. Am J Med 86: 791–800PubMedCrossRefGoogle Scholar
  11. 11.
    Anaissie E, Hachem R, LeGrand K, Lengenne P, Nelson P, Bodey GP. Lack of activity of amphotericin B in systemic murine fusarial infection. JID (in press)Google Scholar
  12. 12.
    Christiansen KJ, Bernard EM, Gold JWM, Armstrong D (1985) Distribution and activity of amphotericin B in humans. J Infect Dis 152: 1037–1043PubMedCrossRefGoogle Scholar
  13. 13.
    Komshian SV, Uwaydah AK, Sobel JD, Crane LR (1989) Fungemia caused by candida species and torulopsis glabrata in the hospitalized patients: Frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11: 379–389PubMedCrossRefGoogle Scholar
  14. 14.
    Horn R, Wong B, Kiehn TE, Armstrong D (1985) Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy. Rev Infect Dis 7: 646–655PubMedCrossRefGoogle Scholar
  15. 15.
    Bodey G P, Vartivarian S (1989) Aspergillosis. Euvr J Clin Microbiol & Inf Dis 8: 413–437CrossRefGoogle Scholar
  16. 16.
    Haron E, Feld R, Tuffnell P, Patterson B, Hasselback R, Matlow A (1987) Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 83: 17–26PubMedCrossRefGoogle Scholar
  17. 17.
    Thaler M, Pastakia B, Shawker TH, O’Leary T, Pizzo PA (1988) Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 108: 88–100PubMedGoogle Scholar
  18. 18.
    Johnson JD, Raff MJ (1984) Fungal splenic abscess. Arch Intern Med 144: 1987–1993PubMedCrossRefGoogle Scholar
  19. 19.
    Graybill JR, Craven PC, Tayloe RL, Williams DM, Magee WE (1982) Treatment of murine cryptococcosis with liposome associated amphotericin B. J Infect Dis 145: 740–745CrossRefGoogle Scholar
  20. 20.
    Meunier F, Gorin N, Kuse RE et al. Safety or ambisome (liposomal amphotericin B, Vestar, USA): Results from a multicenter study. In: Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1990, Atlanta. Ga. Page 130; Abst. #260Google Scholar
  21. 21.
    Lopez-Berestein G, Bodey GP, Fainstein V et al. (1989) Treatment of systemic fungal infections liposomal amphotericin B. Arch Intern Med 149: 2533–2536PubMedCrossRefGoogle Scholar
  22. 22.
    Lazar JT, Kisonski GE, Preiss SJ: Efficacy of ambisome (Iiposomal amphotericin B) in opportunistic pulmonary mycoses. In: Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1990, Atlanta, Ga. Page 181; Abst. #569.Google Scholar
  23. 23.
    Medoff G, Comfort M, Kobayashi GS (1971) Synergistic action of amphotericin G and 5- fluoroucytosine against yeast-like organisms. Proceeding of The Society for Experimental Biology and Medicine 138: 571–574Google Scholar
  24. 24.
    Bennett JE, Dismukes WE, Duma RJ (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New Engl J Med 301: 126–131PubMedCrossRefGoogle Scholar
  25. 25.
    Malet-Martino MC, Martino R, deForni M, Andremont A, Hartmann O, Armand JP (1991) Flucytosine conversion to fluorouracil in humans: Does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection 19: 178–180PubMedCrossRefGoogle Scholar
  26. 26.
    Hiddemann W, Essink ME, Fegeler W, Zuhlsdorf M, Sauerland C, Buchner TH (1991) Antifungal treatment by amphotericin Band 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia. Cancer 68: 9–14PubMedCrossRefGoogle Scholar
  27. 27.
    Winegard JR, Merz WG, Rinaldi MG, Johnson TR, Karp IE, Saral R (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 325: 1274–1277CrossRefGoogle Scholar
  28. 28.
    Jordan WM, Bodey GP, Rodriguez V, Ketchel SJ, Henney J (1979) Miconazole therapy for treatment of fungal disease in cancer patients. Antimicrob Agents Chemother 16: 792–797PubMedGoogle Scholar
  29. 29.
    Winegard JR, Vaughan WP, Braine HG, Merz WG, Saral R (1987) Prevention of fungal sepsis in patients with prolonged neutropenia: A randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 83: 1103–1110CrossRefGoogle Scholar
  30. 30.
    Hughes WT, Bartley DL, Patterson GG, Tufenjeji H (1983) Ketoconazole and candidiasis: A controlled study. J Infect Dis 147: 1060–1063PubMedCrossRefGoogle Scholar
  31. 31.
    Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB (1987) Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 31: 11–15PubMedGoogle Scholar
  32. 32.
    Walsh TJ, Rubin M, Hathorn J et al. (1991) Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. Arch Intern Med 151: 765–770PubMedCrossRefGoogle Scholar
  33. 33.
    Anaissie E, Bodey GP, Kantarjian H et al. (1991) Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91: 142–150PubMedCrossRefGoogle Scholar
  34. 34.
    Kauffman CA, Bradley SF, Ross SC, Weber DR (1991) Hepatosplenic Candidiasis: Successful treatment with fluconazole. Am J Med 91: 137–141PubMedCrossRefGoogle Scholar
  35. 35.
    Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De-beule K (1989) Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. Mycoses 32: 103–108PubMedCrossRefGoogle Scholar
  36. 36.
    van’t Wout JW, Novakova I, Verhagen CAH, Fibbe W, de Pauw BE, vander Meer JWM (1991) The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomized comparative study with amphotericin. B J Infect 22: 45–52CrossRefGoogle Scholar
  37. 37.
    Chow HS, Sarpel SC, Epstein RB (1982) Experimental candidiasis in neutropenic dogs: tissue burden of infection and granulocyte transfusion effects. Blood 59: 328–333PubMedGoogle Scholar
  38. 38.
    Vallejos C, McCredie KB, Bodey GP, Hester JP, Freireich EJ (1975) White blood cell transfusions for control of infections in neutropenic patients. Transfusion 15: 28–33PubMedCrossRefGoogle Scholar
  39. 39.
    Lowenthal RM, Grossman L, Goldman et al. (1975) Granulocyte transfusions in treatment of infections in patients with acute leukemia and aplastic anaemia. Lancet 1: 353–358PubMedCrossRefGoogle Scholar
  40. 40.
    Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay NKC, McGlave P (1991) Candida infections in bone marrow transplant recipients. Bone Marrow Transplantation 8: 177–184PubMedGoogle Scholar
  41. 41.
    Wright DG, Robinchaud KJ, Pizzo PA, Deisseroth AB (1981) Lethal pulmonary reactions associated with the combined use of amphotericin Band leukocyte transfusions. N Engl J Med 304: 1185–1189PubMedCrossRefGoogle Scholar
  42. 42.
    Dana BW, Durie BGM, White RF, Huestis DW (1981) Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity. Blood 57: 90–94PubMedGoogle Scholar
  43. 43.
    Morstyn G, Campbell L, Souza LM et al. (1988) Effects of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1: 667–672PubMedCrossRefGoogle Scholar
  44. 44.
    Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. The role of GM-CSF as adjuvant treatment for patients with bacterial and fungal infections. Rev Infect Dis (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • G. P. Bodey
    • 1
  1. 1.Section of Infectious Diseases, Department of Medical SpecialitiesThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations